What are the limitations of traditional hybridoma technology?

Traditional hybridoma workflows suffer from antibody diversity loss due to cell fusion, genomic instability, and repeated subcloning, resulting in fewer candidates for functional screening. ProBio's Powerdoma™ workflow eliminates subcloning, enabling direct generation of monoclonal hybridoma clones. This shortens timelines by 1‑1.5 months and allows functional screening using hybridoma supernatant at a much earlier stage, improving speed, cost‑effectiveness, and the likelihood of identifying functional antibody hits.

How do you improve the success rate of identifying high-quality leads?

Discovery workflows often face low yields, unstable clones, or limited high-affinity candidates in traditional approaches. ProBio's Powerdoma™ workflow combines high-throughput screening (ELISA, FACS, SPR, cell-based assays), efficient monoclonal hybridoma generation and parallel screening strategies. This results in more positive binders and higher-quality leads compared to conventional methods.

Can hybridoma platforms handle difficult or complex targets?

Targets such as multi-pass membrane proteins or highly conserved antigens can be challenging due to low immunogenicity or immune tolerance. ProBio offers advanced immunization strategies, including mRNA, DNA, VLPs, and whole-cell antigens. This enables successful antibody discovery against challenging targets.

Are there situations traditional hybridoma technology must be used?

There are a few situations where hybridoma technology may be preferred, for example if there are legacy requirements. The main case where there is no choice on method is if flow cytometry is the only method used to screen hybridoma samples. This is not because of biology or antibody technology, but because of instrument (hardware) limitations. Flow cytometry screening requires 96‑well plates, but higher‑throughput hybridoma approaches need 384‑well screening. The antibodies, cells, and biology usually would support a more advanced workflow, but the screening instruments set the limit.

How does traditional hybridoma technology compare to optimized hybridoma technology?

Traditional hybridoma technology leads to longer timelines, lower throughput, and reduced functional hit rates. Overcoming these bottlenecks is essential for faster, more successful antibody discovery. Here is a comparison of some of the key challenges: Traditional hybridoma uses 96-well plates with low to moderate throughput, requires multiple rounds of subcloning, leads to significant antibody diversity loss during fusion and subcloning, takes longer timelines to monoclonal clones (+1‑1.5 months due to subcloning), uses purified antibody for functional screening with few surviving clones entering screening, resulting in lower probability of identifying functional Ab hits and lower overall cost-effectiveness. Optimized hybridoma workflow (Powerdoma™) uses 384-well plates for high throughput, eliminates subcloning, better preserves antibody sequence diversity, enables direct generation of monoclonal hybridoma clones (1‑1.5 months shorter), enables very early functional screening using hybridoma supernatant with many more candidates evaluated, resulting in higher probability of identifying functional Ab hits and higher overall cost-effectiveness.

Hybridoma Antibody Discovery Service

An advanced hybridoma platform that rapidly generates monoclonal cells post‑fusion, eliminates subcloning, and enables direct transition to NGS and recombinant expression, reducing antibody production to six weeks.

Overview

Workflow

Case Studies

Related Services

FAQs

Accelerate Antibody Discovery with Powerdoma™

Streamlined Process

Elimination of sub-cloning steps enables a 3-4 month timeline in comparison with 4-6 months for conventional hybridoma workflows.

Earlier Functional Insights

We enable faster timelines and earlier functional insights, through high-throughput screening based on hybridoma supernatant.

Proven Experience

ProBio has a proven track record at scale, with over 900 hybridoma-based projects and over 60 Powerdoma™ projects executed.

Functional Antibody Sequences in 3 Months

Immunization

Plasma cell enrichment

Cell fusion

8-9 DAYS

384-well plating

Binder screening

7 DAYS

In vitro efficacy assay

7 DAYS

Cell sequencing

7 DAYS

Plasmid preparation

7 DAYS

HTP Ab production

Ab sample

Upgrading conventional hybridoma technology to enable faster functional screening at earlier stages of discovery.

Early Monoclonal Achievement

Positive binders delivered within two weeks, bypassing traditional two-month subcloning process, with maximum preservation of positive binders.

• Improves antibody sequence diversity

• Reduces diversity loss from cell fusion and sub-cloning

Rapid Transition to Sequencing and Assays

Achieve antibody screening in as little as 6 weeks and high-throughput functional assays are enabled earlier via Powerdoma™ supernatant.

• Earlier identification of antibodies with true biological activity

Case Studies

Powerdoma platform enabling early functional antibody lead selection case study

Powerdoma™ enabling early, reliable identification of functional antibodies, accelerating lead selection.

Powerdoma versus traditional hybridoma workflow comparison for DLL3 case study

This study compares the Powerdoma™ platform with traditional hybridoma workflows using a DLL3-target discovery campaign.

Resources

FLYER

Powerdoma™ Hybridoma Discovery Service

Accelerate your discovery timelines by enabling faster functional screening at earlier stages.

Learn More

BROCHURE

Biologics Discovery Services Brochure

Tailored discovery strategies for diverse biologics modalities, designed to enhance success rates.

Learn More

Powerdoma™ upgraded hybridoma platform technical handbook

POSTER

Powerdoma™: An Upgraded Hybridoma Platform

Fast timelines and improved cost-effectiveness for antibody discovery.

Learn More

Discovery of functional antibody leads at early screening stage

HAND

BOOK

Discovery of Functional Antibody Leads at Early Stage of Lead Screening

Solutions to obtain more functional leads at an earlier stage.

Learn More

Request a Quote

Bring the most promising candidates forward with confidence.

Request More Information

Hybridoma Antibody Discovery Service

Accelerate Antibody Discovery with Powerdoma™

Streamlined Process

Earlier Functional Insights

Proven Experience

Functional Antibody Sequences in 3 Months

Case Studies

Powerdoma™ enabling early, reliable identification of functional antibodies, accelerating lead selection.

This study compares the Powerdoma™ platform with traditional hybridoma workflows using a DLL3-target discovery campaign.

Resources

Powerdoma™ Hybridoma Discovery Service

Biologics Discovery Services Brochure

Powerdoma™: An Upgraded Hybridoma Platform

Discovery of Functional Antibody Leads at Early Stage of Lead Screening

Request a Quote

Related Services

Single B Cell Screening

Human Naïve Fab Library Service

Single Domain Antibody Discovery

Antibody Lead Optimization

In Vitro Bioassay

In Vivo Pharmacology

Frequently Asked Questions